Therapy-related myeloid neoplasms: Clinical perspectives

Livio Pagano, Luana Fianchi, Marianna Criscuolo, Emiliano Fabiani, Alessio Maria Edoardo Maraglino, Maria Teresa Voso, Giulia Falconi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)


Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.
Lingua originaleEnglish
pagine (da-a)5909-5915
Numero di pagine7
RivistaOncoTargets and Therapy
Stato di pubblicazionePubblicato - 2018


  • Leukemia
  • Oncology
  • Pharmacology (medical)
  • Prognosis
  • Secondary leukemia
  • Secondary myelodysplastic syndrome
  • Therapy-related myeloid neoplasm


Entra nei temi di ricerca di 'Therapy-related myeloid neoplasms: Clinical perspectives'. Insieme formano una fingerprint unica.

Cita questo